CD19 and diffuse large B-cell lymphoma: The efficacy of the three anti-CD19 CAR T-cell therapies approved for the treatment of R/R DLBCL and t-FL has been demonstrated in several phase II trials showing complete metabolic responses (CMR), ranging from 38% to 54%, and a 2-year OS, ranging from 40% to 58% [2,3,4].